65,437 trials
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants
Neoplasms, Breast
Primary: The Number of Participants With Central Nervous System (CNS) Best Overall Response — 0; 0; 6; 9 Participants
Glaucoma
Primary: Number of Participants With Adverse Events — 10; 11 Participants — p=1.000
Type 1 Diabetes
Primary: For Multiplex PK Profiling: Aggregate Mean Difference in Tmax Between the Analog With Greatest and the Analog With the Least Value of Tmax for Individuals — 24.28 minutes
Cocaine Use Disorder · Anxiety
Primary: Cue Reactivity as Assessed by the Attention Bias (AB) Task — 0.524; 0.519 score on a scale
Multiple Myeloma · Kahler Disease · Plasma-Cell Myeloma
Primary: Number of Participants With Dose Limiting Toxicity According to CTCAE Version 4.03 — 4 Participants
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Clinician's Eyebrow Assessment — 0 score on a scale
Chronic Rhinosinusitis
Primary: Change in Rhinosinusitis Disability Index (RSDI) Score — -8.000; -14.82 units on a scale — p=0.505
Atherosclerosis
Primary: Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week…
Liver Fibrosis · Hepatic Fibrosis · Liver Cirrhosis
Primary: Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score — 25; 14 participants — p=0.73
Anticoagulation
Primary: Rates of Participant Accrual — 107; 51; 50 Participants
HER2+ Metastatic Breast Cancer (MBC)
Primary: Centrally Assessed Progression Free Survival — 8.8; 6.6 months — p=0.0059
Paracervical Block
Primary: Assessment of Pain on a 10-point Visual Analog Pain Scale During the Procedure. — 4.15; 3.38 Score on a scale — p=<.001
Psoriasis Vulgaris
Primary: Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) — -1.60; -4.96; -3.04; -3.96 score on a scale — p=<0.001
Moderate to Severe Psoriasis · Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Primary: Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16 — 7.9; 73.0; 87.1 percentage of participants…